CADTH has introduced a new reimbursement recommendation category to address the unmet needs of those living with a rare or debilitating illness in Canada. The introduction of the time-limited recommendation follows consultations with industry and expert advisory committees. This is an opportunity for drug manufacturers to secure a recommendation for public funding on promising pharmaceuticals for a defined period of time, helping to expedite patient access, while more evidence is collected for a final reimbursement decision.

• Overview of the new reimbursement recommendation pathway
  • Examining the criteria for manufacturer submissions and timelines for deliverables
• Understanding how CADTH, pCPA and industry will work together to implement and streamline this process
• Establishing evidence generation expectations for drug manufacturers